02:51 AM EDT, 10/28/2026 (MT Newswires) -- Idorsia (IDIA.SW) launched a late-stage study to evaluate lucerastat in Fabry disease and signed a co-development and commercialization deal for the investigational drug with Nxera Pharma. Under the Fab-Klear phase 3 study, lucerastat will be assessed as a potential disease-modifying therapy to target kidney manifestations of Fabry disease in adult patients, the Swiss biotech company said Wednesday. Nxera will pay Idorsia 7 million francs for exclusive development and commercialization rights in Japan and selected Asia Pacific territories, excluding China, while Idorsia will be eligible to receive royalties on net sales in the licensed territories. The study, which is aligned with the US Food and Drug Administration's practices, is designed to confirm lucerastat's ability to reduce renal globotriaosylceramide accumulation. The broader phase 3 program, Fabswitch, will evaluate lucerastat against standard-of-care enzyme replacement therapies. The study supports a regulatory filing as early as 2029.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.